US2021069313A1
|
|
Vaccination against diabetes, obesity and complications thereof
|
WO2021074392A1
|
|
Visual detection of pbd induced dna crosslinks
|
WO2021074408A1
|
|
Method for controlling the access to a computer platform and associated devices
|
WO2021074391A1
|
|
Methods for diagnosing nasal intestinal type adenocarcinomas
|
WO2021074338A1
|
|
Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy
|
WO2021069654A1
|
|
Antisense oligonucleotides and their use for the treatment of pain
|
WO2021069593A1
|
|
T cells modified to express mutated cxcr4 or partially deleted and uses thereof
|
WO2021064186A1
|
|
Novel pyridin-2(1h)one derivatives, their preparation and their use for the treatment of pain
|
WO2021064184A1
|
|
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
WO2021064180A1
|
|
Methods and compositions for modulating macrophages polarization
|
WO2021064069A1
|
|
Methods for the treatment of adult t-cell leukemia/lymphoma
|
WO2021064072A1
|
|
Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve
|
WO2021063968A1
|
|
Method and composition for diagnosing chronic obstructive pulmonary disease
|
WO2021058763A1
|
|
Anti-müllerian inhibiting substance antibodies and uses thereof
|
WO2021058729A1
|
|
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
WO2021058744A1
|
|
Use of müllerian inhibiting substance inhibitors for treating cancer
|
WO2021058731A1
|
|
A method for measuring the speed of sound in liver with a specific probe and associated methods and devices
|
WO2021058732A1
|
|
A method for measuring the speed of sound in liver with a moving probe and associated methods and devices
|
WO2021058597A1
|
|
Methods of determining whether a subject is at risk of developing arterial plaques
|
WO2021048292A1
|
|
Methods and compositions for treating melanoma
|